MX356704B - Combinación. - Google Patents

Combinación.

Info

Publication number
MX356704B
MX356704B MX2013008074A MX2013008074A MX356704B MX 356704 B MX356704 B MX 356704B MX 2013008074 A MX2013008074 A MX 2013008074A MX 2013008074 A MX2013008074 A MX 2013008074A MX 356704 B MX356704 B MX 356704B
Authority
MX
Mexico
Prior art keywords
methyl
human
relates
treatment
thiophenecarboxamide
Prior art date
Application number
MX2013008074A
Other languages
English (en)
Other versions
MX2013008074A (es
Inventor
Rakesh Kumar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2013008074A publication Critical patent/MX2013008074A/es
Publication of MX356704B publication Critical patent/MX356704B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La presente invención se relaciona con un método para tratar el cáncer en un humano y con combinaciones farmacéuticas útiles en tal tratamiento; en particular, el método se relaciona con un método de tratamiento del cáncer, que incluye administrar un compuesto que inhibe el proteasoma, y la N-{(1S)-2-amino-1-[(3-flu orofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1H-pirazol-5-il)- 2-tiofencarboxamida, o una sal farmacéuticamente aceptable de la misma, y agentes antineoplásicos adicionales opcionales, a un humano en necesidad del mismo.
MX2013008074A 2011-01-11 2012-01-11 Combinación. MX356704B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161431508P 2011-01-11 2011-01-11
PCT/US2012/020863 WO2012097021A1 (en) 2011-01-11 2012-01-11 Combination

Publications (2)

Publication Number Publication Date
MX2013008074A MX2013008074A (es) 2013-08-09
MX356704B true MX356704B (es) 2018-06-11

Family

ID=46507420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008074A MX356704B (es) 2011-01-11 2012-01-11 Combinación.

Country Status (15)

Country Link
US (6) US20130288984A1 (es)
EP (1) EP2663189B1 (es)
JP (1) JP6100700B2 (es)
KR (1) KR20140053836A (es)
CN (1) CN103298345B (es)
AU (1) AU2012205601B2 (es)
BR (1) BR112013017722A2 (es)
CA (1) CA2824201A1 (es)
EA (1) EA029000B1 (es)
ES (1) ES2689760T3 (es)
IL (1) IL227097B (es)
MX (1) MX356704B (es)
SG (2) SG10201600077RA (es)
WO (1) WO2012097021A1 (es)
ZA (1) ZA201304139B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016004267A (es) * 2013-10-01 2016-07-08 Novartis Ag Combinacion.
EP3065549A4 (en) * 2013-11-07 2017-05-24 Deciphera Pharmaceuticals, LLC Methods for inhibiting tie2 kinase useful in the treatment of cancer
AU2020329956B2 (en) 2019-08-12 2023-11-16 Deciphera Pharmaceuticals, Llc. Ripretinib for treating gastrointestinal stromal tumors
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
KR20220123057A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 비정질 키나아제 억제제 제형 및 이의 사용 방법
CN115243681A (zh) 2019-12-30 2022-10-25 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6328590B1 (en) 2000-07-20 2001-12-11 Emc Corporation Methods and apparatus for controlling attachment of an electronic module with a circuit board connector
JP5136929B2 (ja) * 2004-03-24 2013-02-06 アボット・ラボラトリーズ 三環式ピラゾール系キナーゼ阻害薬
MX2007004514A (es) 2004-10-13 2007-05-09 Pharmacia & Upjohn Co Llc Formas cristalinas de 3-[5-cloro-4-[(2,4-difluorobencil)oxi]-6 oxopirimidin-1(6h)-il]-n-(2-hidroxetil)-4-metilbenzamida.
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CA2620333A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1840114A1 (en) 2006-03-30 2007-10-03 LTB4 Sweden AB Crystalline Leukotriene B4
KR20080108516A (ko) 2006-04-05 2008-12-15 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
WO2007122686A1 (ja) 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
WO2008024484A1 (en) 2006-08-25 2008-02-28 Cougar Biotechnology, Inc. Methods and compositions for treating cancer
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
JP4299327B2 (ja) 2006-08-31 2009-07-22 トヨタ自動車株式会社 可変バルブタイミング装置
WO2008094321A2 (en) 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
NZ575891A (en) 2006-10-13 2011-07-29 Basf Se Hydrates of a phenyluracil
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
MY150059A (en) 2007-10-11 2013-11-29 Astrazeneca Ab Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
DE102008044901A1 (de) 2008-08-29 2010-03-04 Siemens Aktiengesellschaft Verfahren und Vorrichtung zur Auswahl eines Bestrahlungsplans sowie Bestrahlungsanlage
NZ594064A (en) 2009-01-30 2012-08-31 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
UA105794C2 (uk) 2009-06-26 2014-06-25 Новартіс Аг 1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
ES2530436T3 (es) 2009-10-08 2015-03-02 Glaxosmithkline Llc Combinación
KR20140021646A (ko) 2011-04-01 2014-02-20 제넨테크, 인크. Akt 억제제 화합물과 에를로티닙의 조합물, 및 사용 방법
CA2834850A1 (en) 2011-05-03 2012-11-08 University Of Rochester Methods for treating prostate cancer
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
US9353145B2 (en) 2011-10-10 2016-05-31 Zach System Process for preparing 17-substituted steroids
PT2785349T (pt) 2011-11-30 2019-12-11 Astrazeneca Ab Tratamento combinado de cancro
CA3218491A1 (en) 2012-06-04 2013-12-12 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
EP3052098B1 (en) 2013-10-01 2020-12-02 Novartis AG Enzalutamide in combination with afuresertib for the treatment of prostate cancer

Also Published As

Publication number Publication date
CN103298345B (zh) 2016-12-14
SG191724A1 (en) 2013-08-30
US20130288984A1 (en) 2013-10-31
EA201391027A1 (ru) 2014-01-30
AU2012205601B2 (en) 2016-03-24
US20160022641A1 (en) 2016-01-28
AU2012205601A1 (en) 2013-08-01
US20120258933A1 (en) 2012-10-11
EP2663189B1 (en) 2018-07-04
WO2012097021A1 (en) 2012-07-19
BR112013017722A2 (pt) 2016-07-12
US20170100449A1 (en) 2017-04-13
CA2824201A1 (en) 2012-07-19
EP2663189A1 (en) 2013-11-20
ES2689760T3 (es) 2018-11-15
EP2663189A4 (en) 2014-06-11
US20160375086A1 (en) 2016-12-29
US20150119337A1 (en) 2015-04-30
JP6100700B2 (ja) 2017-03-22
MX2013008074A (es) 2013-08-09
KR20140053836A (ko) 2014-05-08
JP2014507412A (ja) 2014-03-27
EA029000B1 (ru) 2018-01-31
US10449226B2 (en) 2019-10-22
IL227097B (en) 2018-02-28
ZA201304139B (en) 2014-02-26
SG10201600077RA (en) 2016-02-26
CN103298345A (zh) 2013-09-11

Similar Documents

Publication Publication Date Title
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
PH12016502355A1 (en) Pharmaceutical composition
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
MX2013008074A (es) Combinacion.
MX2020002150A (es) Terapia de combinación para el tratamiento del cáncer.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
MY179607A (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
MX2014003180A (es) Metodos para tratar vhc.
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
WO2016133903A3 (en) Combination therapy for cancer treatment
IN2014DN10670A (es)
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
PH12016502352A1 (en) Pharmaceutical composition
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
TW201613578A (en) Pharmaceutical combinations
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
EA201491427A1 (ru) Замещенные фенилимидазопиразолы и их применение
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX368640B (es) Composición farmacéutica para tratar inflamación y dolor.
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
MX2017002627A (es) Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak.
MX2014013491A (es) Metodos para mantener, tratar o mejorar la funcion cognitiva.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: NOVARTIS AG

FG Grant or registration